Impact of uricosurics on mortality outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam

Research output: Contribution to journalReview articlepeer-review


Objectives: To determine risks associated with uricosurics in COVID-19 patients. Methods: A systematic review and meta-analysis was conducted by systematically searching electronic databases. Key findings: The pooled analysis of the included trials revealed that the use of uricosurics was not associated with the risk of mortality (pooled odds ratio [OR] = 1.03, 95% confidence interval [CI]: 0.94-1.12). However, there is a potential mortality benefit associated with the use of ascorbic acid (pooled OR = 0.78, 95% CI: 0.65-0.94). Conclusions: The findings confirmed the safety of uricosurics in COVID-19 patients, despite their potential to cause uric acid excretion, which may possess antioxidant properties.
Original languageEnglish
Pages (from-to)259-264
Number of pages6
JournalInternational Journal of Pharmacy Practice
Issue number3
Early online date4 Mar 2024
Publication statusPublished - 1 Jun 2024

Cite this